ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 597,52
-0,23%
Dow Jones
42 063,36
0,09%
DAX
18 720,01
-1,47%
Brent Oil
74,135
-0,25%
Bitcoin
63 207,63
0,41%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Axsome Therapeutics Inc (AXSM)

  7. Axsome Therapeutics Inc (AXSM) Actualités

AXSM

Axsome Therapeutics (AXSM)

Axsome Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AXSM
DateHeureSourceTitreSymboleSociété
04/09/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
04/09/202413h00GlobeNewswire Inc.Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of MigraineNASDAQ:AXSMAxsome Therapeutics Inc
27/08/202413h00GlobeNewswire Inc.Axsome Therapeutics to Participate in Investor Conferences in SeptemberNASDAQ:AXSMAxsome Therapeutics Inc
21/08/202413h00GlobeNewswire Inc.Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.NASDAQ:AXSMAxsome Therapeutics Inc
10/08/202401h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
09/08/202423h07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
05/08/202422h36Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AXSMAxsome Therapeutics Inc
05/08/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AXSMAxsome Therapeutics Inc
05/08/202413h00GlobeNewswire Inc.Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
05/08/202411h46IH Market NewsU.S. Index Futures and Oil Prices Plunge on Recession ConcernsNASDAQ:AXSMAxsome Therapeutics Inc
11/07/202413h00GlobeNewswire Inc.Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5NASDAQ:AXSMAxsome Therapeutics Inc
05/06/202413h35GlobeNewswire Inc.Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem LaboratoriesNASDAQ:AXSMAxsome Therapeutics Inc
04/06/202413h00GlobeNewswire Inc.Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
03/06/202413h00GlobeNewswire Inc.Axsome Therapeutics Supports Alzheimer’s & Brain Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
30/05/202413h00GlobeNewswire Inc.Axsome Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
29/05/202413h00GlobeNewswire Inc.Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024NASDAQ:AXSMAxsome Therapeutics Inc
28/05/202413h00GlobeNewswire Inc.Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) MeetingNASDAQ:AXSMAxsome Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.Axsome Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202414h09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202413h00GlobeNewswire Inc.Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
01/05/202413h00GlobeNewswire Inc.Axsome Therapeutics Recognizes May as Mental Health Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
15/04/202413h00GlobeNewswire Inc.Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:AXSMAxsome Therapeutics Inc
10/04/202413h00GlobeNewswire Inc.Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6NASDAQ:AXSMAxsome Therapeutics Inc
01/04/202413h00GlobeNewswire Inc.Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating DisorderNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202412h00GlobeNewswire Inc.Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202411h30GlobeNewswire Inc.Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyNASDAQ:AXSMAxsome Therapeutics Inc
19/03/202412h00GlobeNewswire Inc.Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderNASDAQ:AXSMAxsome Therapeutics Inc
05/03/202413h00GlobeNewswire Inc.Axsome Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
27/02/202413h00GlobeNewswire Inc.Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
23/02/202414h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AXSMAxsome Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AXSM

Dernières Valeurs Consultées

EU
GLE
Societe Generale
EU
MC
Lvmh Moet Hennessy Louis...
EU
SGO
Cie de SaintGobain
EU
AI
Air Liquide
EU
RNO
Renault
EU
LR
Legrand
NASDAQ
GOOGL
Alphabet
COIN
ADAUSD
Cardano
COIN
XRPUSD
Ripple
EU
ACA
Credit Agricole
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés